CHU Nice - Hôpital Pasteur 2
Nice, Alpes-Maritimes, 06000, France
NCT Number: NCT06088563
Immune response to influenza vaccine in kidney transplant patients
Looking for future studies?
Notify Me18 year–100 year
All sexes
Interventional
Not applicable
Nice, Alpes-Maritimes, 06000, France
Seasonal influenza vaccination is recommended for kidney transplant patients, as influenza is responsible for significant morbidity and mortality in this immunocompromised population. Nevertheless, injection of influenza vaccine induces a protective immune response in only 20% to 40% of patients. Today, there are no recommendations regarding the injection time of influenza vaccine in the general population or in immunocompromised patients. In this context, recent studies conducted in healthy subjects have shown that the time of vaccination can have an impact on vaccine efficacy. This is the case for BCG, influenza, COVID-19. On this basis, we formulate the main hypothesis that the administration of influenza vaccine to kidney transplant patients would be more effective when carried out in the morning than in the evening.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Injection of the vaccine in renal transplant patients.
Other names: EFLUELDA - Fluzone High-Dose Quadrivalent
Time frame: 7 months
Seroconversion will be defined as an increase in antibody titer of at least 4-fold (≥4) over pre-vaccination titer AND an antibody titer ≥ 1:40 (seroprotection) four weeks post-vaccination, for at least one of the three vaccine antigens.
Time frame: 8 months
Comparing the number of seasonal influenza virus infections in kidney transplant patients between a group of patients vaccinated in the morning and a group vaccinated in the evening.
The occurrence of influenza, as confirmed by a PCR test, will be noted in the follow-up consultation.
Time frame: 7 months
In kidney transplant patients, compare the evolution of antibody titres reacting with vaccine antigens 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.
The titer of antibodies reacting with vaccine antigens is measured by ELISA ;
Time frame: 7 months
To compare in kidney transplant patients the evolution of the number of memory B cells reacting with vaccine antigens 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.
The number of memory B cells reacting with vaccine antigens will be measured by ELISPOT ;
Time frame: 7 months
Comparing the evolution of CD4+ T cells reacting with vaccine antigens in kidney transplant patients 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.
The number of CD4+ T cells reacting with vaccine antigens will be measured by in vitro proliferation assay;
Time frame: 7 months
Comparing the evolution of CD8+ T cells reacting with vaccine antigens in kidney transplant patients 4 weeks after influenza vaccination between a group of patients vaccinated in the morning and a group of patients vaccinated in the evening.
The number of CD8+ T cells reacting with vaccine antigens will be measured by in vitro proliferation assay;
Centre Hospitalier Universitaire de Nice
Other
Acronym: CHRONOVAX
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06716567
Immunoglobulins, Infections
Brussels, Belgium
View Trial DetailsNCT05869201
Infections, Influenza
Kol'tsovo, Novosibirsk Oblast, Russia
View Trial DetailsNCT05470582
Infections, Influenza, Human
Saint Petersburg, Russia
View Trial DetailsNCT05457894
Infections, Influenza, Human
Barnaul, Altai Territory, Russia
View Trial Details